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A B S T R A C T
Background: In the current meta-analysis of randomized controlled trials (RCTs), the eﬀects of vitamin D sup-
plementation on mental health, and biomarkers of inﬂammation and oxidative stress in patients with psychiatric
disorders are assessed.
Methods: The following databases were search up to March 2019: MEDLINE, EMBASE, Web of Science, and
Cochrane Central Register of Controlled Trials. The quality of the relevant extracted data was assessed according
to the Cochrane risk of bias tool. Data were pooled by the use of the inverse variance method and expressed as
mean diﬀerence with 95% Conﬁdence Intervals (95% CI).
Results: Eleven eﬀect sizes from nine studies were included in the ﬁnal analyses. A pooled analysis of 9 eﬀect
sizes showed a signiﬁcant reduction in Beck Depression Inventory (BDI) score following supplementation with
vitamin D [weighted mean diﬀerence (WMD): -3.91; 95% CI: -5.15 -2.66), I2= 85.9%]. Combining data from
two available studies on the eﬀects of vitamin D supplementation on Pittsburgh Sleep Quality Index (PSQI) also
revealed a signiﬁcant reduction in this score following the intervention (WMD: -1.78; 95% CI: -2.28, -1.28). In
addition, there were signiﬁcant increase in glutathione (GSH) through 3 studies (WMD: 180.70; 95% CI: 6.76,
354.64), and in total antioxidant capacity (TAC) through 3 studies (WMD: 90.09; 95% CI: 56.36, 123.82) after
vitamin D supplementation. Combining data from ﬁve studies, we found a signiﬁcant reduction in C-reactive
protein (CRP) concentrations after vitamin D supplementation (WMD: -1.74; 95% CI: -2.82, -0.66).
Conclusions: Overall, the current meta-analysis demonstrated that taking vitamin D supplements among patients
with psychiatric disorders had beneﬁcial eﬀects on BDI, PSQI, GSH, TAC and CRP levels, but did not aﬀect other
biomarkers of inﬂammation and oxidative stress.
1. Introduction
Psychiatric disorders, as a group of diseases which mainly included
depression, anxiety, substance-related disorders and schizophrenia, are
prevalent worldwide (Hyman et al., 2006). Almost one third of adults
experienced a common mental disorder across their lifetimes (Steel
et al., 2014). These conditions are associated with excess premature all-
cause mortality and increased global burden of disease (Charlson et al.,
2015). Current estimates indicated that psychiatric disorders accounted
for 13% of global disability-adjusted life-years (Vigo et al., 2016).
Chronic inﬂammatory state and elevated reactive oxygen species (ROS)
present as major components of mental illness pathology (Najjar et al.,
2013).
Based on the results of observational studies, psychiatric disorders
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are associated with lower vitamin D status (Belvederi Murri et al.,
2013). Vitamin D is a lipid-soluble vitamin, which has several hormonal
functions. Beside to calcium-phosphorus homeostasis and bone meta-
bolism, it involves in antioxidant defense system, anti-inﬂammatory
process, and immune modulation (Sassi et al., 2018). Vitamin D is
proposed to act as a membrane antioxidant. It also increases the gene
expression levels of antioxidants agents (Brown and Slatopolsky, 2008).
Vitamin D also decreases cytokine generation via inhibitory eﬀects on
the activation and expression of nuclear factor kappa B (NF-κB) and
other related genes (Cohen-Lahav et al., 2006). The evidence has sug-
gested that vitamin D may improve mood and behavior by modulating
the biosynthesis of neurotransmitters and neurotrophic factors (Macova
et al., 2017).
Previously, Spedding (2014) performed a meta-analysis to examine
the eﬀects of vitamin D supplementation in the management of de-
pression and concluded that taking vitamin D supplements improved
depressive symptoms in studies without biological ﬂaws. Another meta-
analysis by Li et al. (2014) showed that vitamin D supplementation did
not improve depressive score in adults; while, all of the included trials
except one, conducted among participants without clinical depression.
Two other meta-analyses failed to ﬁnd any beneﬁcial eﬀects of vitamin
D supplementation on depressive symptoms among individuals with
diﬀerent health conditions (Gowda et al., 2015; Shaﬀer et al., 2014).
Several evidence evaluated the eﬀects of vitamin D supplementation on
oxidative stress and inﬂammatory markers. Recently, a systematic re-
view and meta-analysis conducted by Sepidarkish et al. (2019) revealed
that vitamin D supplementation signiﬁcantly increased some anti-
oxidants levels and led to a remarkable decrease in malondialdehyde
(MDA) values, while the serum nitric oxide (NO) concentrations were
unchanged. Our previous study indicated that vitamin D supple-
mentation improved plasma levels of oxidative stress markers and de-
creased C-reactive protein (CRP) values among patients with diabetes
(Mansournia et al., 2018). Several randomized clinical trials (RCTs)
have indicated a promising eﬀect of vitamin D supplementation on
mental health, inﬂammatory and oxidative stress parameters in patients
with psychiatric disorders; others did not report such eﬀect. However,
the sample size of these trials was small, the dosage and frequency of
supplementation were diﬀerent, the quality of studies was variable;
therefore, the results were inconsistent.
This meta-analysis was carried out to summarize the available evi-
dence of RCTs to clarify the eﬀects of vitamin D supplementation on
parameters of mental health, inﬂammation and oxidative stress markers
in patients with psychiatric disorders.
2. Methods
2.1. Search strategy
We used the relevant published articles which are extracted from
Medline, Embase, Cochrane Library, and Web of Science databases until
March 2019 for identifying Eligible RCTs using manually searching the
reference list of the retrieved papers. In this regard, we applied the
Databases of International Standard Randomized Controlled Trial
Number Register and Meta-register for obtaining the RCTs for all on-
going trials. Reports retrieved that assessed the eﬀects of vitamin D
supplementation on various mental health parameters, and oxidative
stress and inﬂammation markers by applying the following MeSH and
text words, including intervention [("colecalciferol" AND "vitamin D"
AND "ergocalciferol" AND "supplementation" OR "intake")], and out-
comes ["Beck Depression Inventory (BDI)" OR "CRP" OR "NO" OR "MDA"
OR "total antioxidant capacity (TAC)" OR "glutathione (GSH)"], and
patients ["psychotic disorder" OR "depressive disorders" OR "mental
disorder" OR "mental health" OR "mood" OR "depression" OR "attention
deﬁcit disorder with hyperactivity" OR "attention deﬁcit hyperactivity
disorder (ADHD)" OR "autism spectrum disorder" OR "Tourette syn-
drome" OR "obsessive-compulsive disorder" OR "anxiety disorder" OR
"AD" OR "schizophrenia" OR "bipolar disorder"]. Moreover, we used
additional manual searches (i.e., reference lists of associated reports;
former review studies were assessed to elevate sensitivity in search
procedure.
2.2. Inclusion and exclusion criteria
All CTs with either parallel or cross-over design that investigated
the eﬀect of any dosages of vitamin D supplementation on mental
health parameters, and oxidative stress and inﬂammation markers, and
used placebo as the control group among patients with psychiatric
disorders were included. Animal experiments, in vitro studies, case re-
ports, observational studies, studies that did not have a control group,
and those studies that did not achieve the least quality score were ex-
cluded. Studies in which vitamin D analogs were used as the inter-
vention and those without placebo group were also excluded.
2.3. Data extraction and quality assessment
We employed two authors (EA and HM) independently which ex-
tracted the data and evaluated its quality applying the Cochrane
Collaboration risk of bias tool and standard forms, respectively (Higgins
et al., 2011; Mansournia et al., 2017). This tool is depended on in-
formation from the following domains, including allocation conceal-
ment, blinding of cases and outcome evaluation, randomization gen-
eration, selective outcome reporting, incomplete outcome data, and
other sources of bias. The disagreements among two authors were re-
solved by third author (ZA). Eligible studies based on the following
characteristics were abstracted: publication year, ﬁrst authors’ name,
study design, study location, age, sex, and body composition and/or
metabolic proﬁles of study subjects and related measures of variance,
Articles screened by title and 
abstract (n=131)
Full text articles assessed for 
eligibility (n=28)
Studies included in this study (n=9)
Article excluded (n=1268) due to duplicate 
articles, not randomized controlled trials, 
review and not human 
Excluded non-relevant articles (n=103)
Articles excluded (n=17):
1. Data presentation inappropriate for meta-
analysis (n=17)
2. Full text was not available (n=2)
Articles identified through 
electronic database search 
(n=1399)
Fig. 1. Literature search and review ﬂowchart for selection of studies.
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number of cases in the control and intervention groups, and duration of
the intervention.
2.4. Heterogeneity and publication biases
In the present meta-analysis study, chi-square test (Overvad et al.,
1999), and quantiﬁed by the I2 statistic (Higgins et al., 2003) were used
for assessing the heterogeneity of the results in the included reports.
The funnel plot used for evaluating the publication bias and also Egger's
test performed to assess statistical signiﬁcance (Egger et al., 1997).
2.5. Summary measures
We obtained the mean diﬀerence and carried out the meta-analyses
for the impacts of vitamin D supplementation on oxidative stress and
inﬂammation markers and diﬀerent mental health parameters, for all
included RCTs by applying the inverse variance approach. To reach the
impact sizes the change score approach was applied, because the cor-
relations between end measurements and baseline were more than 1/2
(Matthews, 2006). The random eﬀect model was employed to study the
pooled mean diﬀerence with 95 % conﬁdence intervals (CIs). If het-
erogeneity was high between studies, random eﬀect model was used to
calculate the pooled estimates. Baseline and ﬁnal values of the men-
tioned outcomes for both intervention and placebo groups were ex-
tracted from the included studies to calculate mean changes with
standard deviation (SD) for each variable. In addition, we used sub-
group analysis to detect probable sources of heterogeneity using a ﬁxed-
eﬀects model. P-values< 0.05 were obtained as statistically signiﬁcant.
Review Manager 5.3 and Stata version 11.0 (Stata Corp., College Sta-
tion, TX) were used for statistical analyses.
3. Results
3.1. Study characteristics
In total, data from nine studies with 11 eﬀect sizes were included in
the current meta-analysis. Flow-diagram of study selection is shown in
Fig. 1. Characteristics of included studies are presented in Table 1. A
total of 1348 individuals aged 18 to 65 years old (671 in intervention
and 677 in control groups) were participated in these studies. The study
duration was varied between 8 and 52 weeks. Vitamin D was used in
usual dose (50,000 IU) in some studies, while the others used high
dosages of vitamin D.
3.2. Findings for the eﬀects of vitamin D supplementation on parameters of
mental health
A pooled analysis of 9 eﬀect sizes from 8 studies showed a sig-
niﬁcant reduction in BDI score following vitamin D supplementation
[weighted mean diﬀerence (WMD): -3.91; 95% CI: -5.15, -2.66),
I2= 85.9%] (Table 2 & Fig. 2A). Subgroup analyses were performed to
investigate the potential sources of between-study heterogeneity. We
stratiﬁed studies based on study location, supplement dosage, study
duration (< 12 vs.≥12 weeks), study sample size (< 50 vs.≥50), and
outcome assessment method (BDI/DSM-IV/other methods or combi-
nation) (Table 3). Findings remained unchanged in all subgroup ana-
lyses. In addition, combining data from two available studies on the
eﬀects of vitamin D supplementation on PSQI also revealed a signiﬁcant
reduction in this score following the intervention (WMD: -1.78; 95% CI:
-2.28, -1.28) (Table 2 & Fig. 2B).
3.3. Findings for the eﬀects of vitamin D supplementation on oxidative stress
Our meta-analysis showed a signiﬁcant increase in GSH through 3
studies (WMD: 180.70; 95% CI: 6.76, 354.64) and in TAC levels
Table 1
Characteristics of the studies included in the analysis.
Authors (ref) Publication year Country Sample size (control/
intervention)
Duration (wk) Age (years) Intervention (type and dosage)
Mozaﬀari-Khosravi et al.
(2013)
2013 Iran 34/36 12 20–60 150,000 IU vitamin D single injection
34/39 12 20–60 300,000 IU vitamin D single injection
Khoraminya et al. (2013) 2013 Iran 20/20 8 18–65 1,500 IU vitamin D3+ 20mg ﬂuxetine
Sepehrmanesh et al. (2016) 2016 Iran 18/18 8 18–65 50,000 IU/week vitamin D
Wang et al. (2016) 2016 China 364/362 52 ≥ 18 50,000 IU/week vitamin D3
Ghaderi et al. (2017) 2017 Iran 34/34 12 25–70 50,000 IU/2 weeks vitamin D
Majid and Ahmad (2018) 2018 Iran 45/44 8 20–50 50,000 IU/2 weeks vitamin D
Zhang et al. (2018) 2018 China 64/56 8 ≥18 100,000 IU/week vitamin D3
Ghaderi et al. (2019) 2019 Iran 30/30 12 25–65 50,000 IU/2 weeks vitamin D+ probiotic
Far et al. (2018) 2018 Iran 20/19 8 18–65 50,000 IU/week vitamin D3+ cognitive
behavioral therapy
13/13 8 18–65 50,000 IU/week vitamin D3+ drug therapy
Table 2
The eﬀects of vitamin D supplementation on markers of mental health, inﬂammation and oxidative stress.
Variables Number of eﬀect sizes Weighted mean diﬀerence CI 95% Heterogeneity
I2 (%) P-value heterogeneity
BDI 9 -3.91 -5.15, -2.66 85.9 < 0.001
PSQI 2 -1.78 -2.28, -1.28 0.0 0.32
GSH 3 180.70 6.76, 354.64 85.8 < 0.01
TAC 3 90.09 56.36, 123.82 0.0 0.55
MDA 2 -0.19 -0.77, 0.40 86.9 < 0.01
NO 2 -0.82 -1.97, 0.32 11.1 0.28
CRP 5 -1.74 -2.82, -0.66 89.3 < 0.001
BDI, Beck Depression Inventory; PSQI, Pittsburgh Sleep Quality Index; GSH, Glutathione; TAC, Total Antioxidant Capacity; MDA, Malondialdehyde; NO, Nitric Oxide;
CRP, C-Reactive Protein.
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Overall  (I-squared = 0.0%, p  = 0.322)
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Majid MS (2018)
Ghaderi A (2017)
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-1.78 (-2.28, -1.28)
-1.91 (-2.47, -1.35)
-1.30 (-2.37, -0.23)
WMD (95% CI)
100.00
%
78.42
21.58
Weight
0-2.47 2.47
NOTE: Weights are from random effects analysis
Overall  (I-squared = 85.6%, p = 0.000)
Sepehrmanesh Z (2015)
Zhang L (2018)
Far ZM (a) (2018)
Far ZM (b) (2018)
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Khoraminya N  (2013)
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ID
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-7.20 (-10.21, -4.19)
-2.00 (-2.07, -1.93)
-5.55 (-7.73, -3.37)
-4.20 (-7.08, -1.32)
WMD (95% CI)
100.00
4.92
13.92
16.61
9.52
8.12
8.64
17.77
11.46
9.05
Weight
%
0-10.2 10.2
NOTE: Weights are from random effects analysis
Overall  (I-squared = 85.9%, p = 0.000)
Zhang L (2018)
Ghaderi A (2017)
Study
Khoraminya N  (2013)
ID
Wang Y (2016)
Far ZM (a) (2018)
Mozaffari-Khosravi H (b) (2013)
Far ZM (b) (2018)
Sepehrmanesh Z (2016)
Mozaffari-Khosravi H (a) (2013)
-3.91 (-5.15, -2.66)
-1.60 (-3.14, -0.06)
-3.30 (-6.50, -0.10)
-5.55 (-7.73, -3.37)
WMD (95% CI)
-2.00 (-2.07, -1.93)
-4.00 (-4.78, -3.22)
-7.20 (-10.21, -4.19)
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13.90
8.17
%
11.48
Weight
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16.52
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9.55
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-10.2 10.2
Fig. 2. Meta-analysis mental health and biomarkers of inﬂammation and oxidative stress weighted mean diﬀerence estimates for A) BDI, B) PSQI, C) GSH, D) TAC, E)
MDA, F) NO, and G) CRP in the vitamin D supplements and placebo groups (CI=95%).
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through 3 studies (WMD: 90.09; 95% CI: 56.36, 123.82) after vitamin D
supplementation (Table 2 & Fig. 2C and D). In contrast, no signiﬁcant
change was found in MDA through 2 studies (WMD: -0.19; 95% CI:
-0.77, 0.40) and NO levels through 2 studies (WMD: -0.82; 95% CI:
-1.97, 0.32) following vitamin D supplementation (Table 2 & Fig. 2E
and F).
3.4. Findings for the eﬀects of vitamin D supplementation on CRP levels
Combining data from ﬁve studies, we found a signiﬁcant reduction
in CRP concentrations after vitamin D supplementation (-1.74; 95% CI:
-2.82, -0.66) (Table 2 & Fig. 2 G), which remained unchanged in all
subgroup analyses, even in stratiﬁcation by the participants’ health
condition (depression/other mental disorders) (Table 3).
4. Discussion
In this meta-analysis, for the ﬁrst time, we pooled data from avail-
able evidence of vitamin D supplementation in patients with psychiatric
disease. The results of present study revealed that the consumption of
vitamin D supplements improved BDI, PSQI, GSH, TAC and CRP levels,
but did not aﬀect other biomarkers of inﬂammation and oxidative
C
NOTE: Weights are from random effects analysis
Overall  (I-squared = 85.8%, p = 0.001)
Study
Ghaderi A (2017)
ID
Ghaderi A (2019)
Sepehrmanesh Z (2016)
180.70 (6.76, 354.64)
243.40 (152.36, 334.44)
WMD (95% CI)
53.60 (-3.19, 110.39)
383.00 (13.10, 752.90)
100.00
%
41.01
Weight
44.03
14.95
0-753 753
D
Overall  (I-squared = 0.0%, p = 0.559)
ID
Study
Ghaderi A (2019)
Sepehrmanesh Z (2016)
Ghaderi A (2017)
90.09 (56.36, 123.82)
WMD (95% CI)
71.80 (21.62, 121.98)
88.00 (4.66, 171.34)
112.50 (58.08, 166.92)
100.00
Weight
%
45.20
16.38
38.42
0-171 171
Fig. 2. (continued)
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stress.
4.1. Eﬀects on mental health
Psychiatric disorders are associated with mood and emotional
challenges leading to impaired individual function and quality of life
(Hyman et al., 2006). These conditions are accompanied by increased
oxidative stress and the inﬂammatory state (Maes et al., 2011). In the
present study, we demonstrated that vitamin D supplementation de-
creased BDI score and PSQI in patients with psychiatric diseases.
Similar to our ﬁndings a meta-analysis by Spedding (2014) revealed
that vitamin D supplementation led to a signiﬁcant reduction in the
indicators of depression in studies without biological ﬂaws. Whereas,
Shaﬀer et al. (2014) demonstrated that vitamin D supplementation had
no signiﬁcant eﬀects on depressive symptoms in patient with various
underlying conditions, while the authors found a moderate improve-
ment across trials that recruited patients with depression. In contrast to
our ﬁndings, in a meta-analysis by Gowda et al. (2015), vitamin D
supplementation resulted in no signiﬁcant reduction in depression
symptoms. Another meta-analysis by Li et al. (2014) also revealed that
E
NOTE: Weights are from random effects analysis
Overall  (I-squared = 86.9%, p  = 0.006)
ID
Ghaderi A (2019)
Ghaderi A (2017)
Study
-0.19 (-0.77, 0.40)
WMD (95% CI)
-0.50 (-0.85, -0.15)
0.10 (-0.14, 0.34)
100.00
Weight
47.55
52.45
%
0-.852 .852
F
Overall  (I-squared = 11.1%, p = 0.289)
Ghaderi A (2019)
Study
Ghaderi A (2017)
ID
-0.82 (-1.97, 0.32)
-0.50 (-1.79, 0.79)
-2.00 (-4.45, 0.45)
WMD (95% CI)
100.00
78.34
%
21.66
Weight
0-4.45 4.45
Fig. 2. (continued)
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vitamin D supplementation had no signiﬁcant eﬀects on depressive
symptoms in adults; however, most of the included RCTs investigated
the eﬀects of vitamin D supplementation in participants at risk of de-
pression and only one study was conducted in patients with MDD.
Based on previous investigations, depressive symptoms increase the risk
of suicide in patients with psychiatric disease (Fiedorowicz et al.,
2019). This may suggest that improving depression scores in patients
suﬀered from mental disorders could have protective eﬀects against
fatality rate. In addition, there is an association between BDI score and
health-related quality of life (Riihimaki et al., 2016). There are several
mechanisms by which vitamin D may improve psychological symptoms.
It is proposed that vitamin D activates receptors in the brain, in areas
which it is implicated in the regulation of behavior, stimulates neuro-
trophin release, and protects the brain against oxidative damages and
inﬂammation (Cherniack et al., 2009). In addition, it is proposed that
increased neural levels of calcium as a result of increased glutamate, is a
major factor for the onset of depression. Vitamin D modulates the ex-
pression of calcium pumps and buﬀers which results in decreasing
calcium levels and regulating calcium signaling pathways (Berridge,
2017). Moreover, vitamin D induces the transcription of serotonin-
synthesizing gene tryptophan hydroxylase 2 in the brain, which con-
tains a vitamin D response element (VDRE) and contributes to im-
proving psychiatric symptoms (Patrick and Ames, 2014).
4.2. Eﬀects on biomarkers of oxidative stress
Results of the present study showed that vitamin D supplementation
signiﬁcantly improved TAC and GSH levels, but did not inﬂuence MDA
levels. Recently, in a study conducted by Sepidarkish et al. (2019), vi-
tamin D supplementation signiﬁcantly increased TAC and GSH levels,
and led to a remarkable reduction in MDA levels; while serum NO
concentrations were unchanged. Our previous work indicated that vi-
tamin D supplementation in diabetic patients increased NO, GSH and
TAC levels and decreased MDA values (Mansournia et al., 2018). An-
other meta-analysis revealed that vitamin D supplementation led to a
signiﬁcant rise in TAC and a signiﬁcant decrease in MDA levels, while
GSH and NO levels remained unchanged (Akbari et al., 2018). The
elevated oxidative burden may contribute to endothelial dysfunction
G
NOTE: Weights are from random effects analysis
Overall  (I-squared = 89.3%, p = 0.000)
Ghaderi A (2019)
Ghaderi A (2017)
Sepehrmanesh Z (2016)
Zhang L (2018)
ID
Study
Wang Y (2016)
-1.74 (-2.82, -0.66)
-2.00 (-3.11, -0.89)
-4.20 (-6.08, -2.32)
-0.01 (-0.92, 0.90)
-2.70 (-3.61, -1.79)
WMD (95% CI)
-0.78 (-0.81, -0.75)
100.00
19.50
14.07
20.91
20.95
Weight
%
24.57
0-6.08 6.08
Fig. 2. (continued)
Table 3
Subgroup analyses for the eﬀects of vitamin D supplementation on markers of mental health, inﬂammation and oxidative stress.
Variables Subgroups Number of eﬀect sizes Pooled WMD 95% CI I2 (%) Between-study I2 (%)
BDI Study location Iran 7 -4.34 -4.99, -3.69 0.7 < 0.001
China 2 -2.00 -2.07, -1.93 0.0
Supplement dosage Usual 6 -2.02 -2.09, -1.95 88.1 < 0.001
High 3 -3.03 -4.27, -1.79 82.3
Study duration < 12 weeks 5 -3.79 -4.43, -3.15 65.0 < 0.001
≥12 weeks 4 -2.00 -2.07, -1.94 79.0
Study sample size n < 50 4 -4.24 -4.94, -3.54 0.0 < 0.001
n≥ 50 5 -2.00 -2.07, -1.93 72.5
Outcome assessment method BDI 4 -4.25 -4.96, -3.55 31.3 < 0.01
DSM-IV 3 -3.04 -4.25, -1.82 77.6
Not reported 2 -2.00 -2.07, -1.93 0.0
CRP Study location Iran 3 -1.23 -1.89, -0.57 89.1 0.18
China 2 -0.78 -0.81, -0.75 94.2
Outcome assessment method DSM-IV 3 -1.52 -2.08, -0.97 88.8 0.009
Not reported 2 -0.78 -0.81, -0.75 92.1
Health condition Depression 3 -0.78 -0.81, -0.75 99.89 < 0.001
Other mental disorders 2 -2.57 -3.53, -1.61 74.3
Study duration < 12 weeks 2 -1.36 -2.01, -0.72 94.1 0.07
≥12 weeks 3 -0.78 -0.81, -0.75 88.4
BDI: Beck Depression Inventory; CRP: C–Reactive Protein.
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which is a shared mechanism for the association between depressive
disorders and CVD (Najjar et al., 2013). Oxidative stress increases the
risk of atherosclerosis in individuals with depression (Yager et al.,
2010). Decreased antioxidant capacity and increased ROS damage
protein, DNA, and membrane fatty acids which results in cell apoptosis,
neurodegeneration and volumetric changes in the brain (Maes et al.,
2011). Moreover, multiple studies have reported that antioxidant
therapy improved clinical symptoms of psychiatric disorders (Pandya
et al., 2013). The evidence suggests that vitamin D may increase the
gene expression of several antioxidants including GSH, glutathione
peroxidase, and superoxide dismutase through binding to VDRE (Brown
and Slatopolsky, 2008). In addition, the structural similarities between
vitamin D and cholesterol and ergosterl are responsible for its mem-
brane antioxidant properties (Wiseman, 1993). Vitamin D intake can
improve oxidative stress through its antioxidant properties (Cetinkalp
et al., 2009), and decreasing production of ROS and pro-inﬂammatory
cytokines (Jain and Micinski, 2013).
4.3. Eﬀects on inﬂammatory markers
Our ﬁndings indicated that vitamin D supplementation signiﬁcantly
reduced CRP, but did not aﬀect NO levels. While other studies indicated
that vitamin D supplementation signiﬁcantly decreased CRP levels in all
(Sepidarkish et al., 2019), as well as, among patients with diabetes
(Mansournia et al., 2018), or had beneﬁcial eﬀects on serum CRP
concentrations (Akbari et al., 2018). However, a meta-analysis by
Rodriguez et al. (2018) failed to ﬁnd any signiﬁcant improvement in
plasma CRP values among patients with heart failure. Activation of
inﬂammatory responses is one of the contributing mechanisms which
increase the risk of metabolic syndrome in patients with psychiatric
disorders (Penninx and Lange, 2018). The diﬀerence in dosages of vi-
tamin D used, the type of vitamin D used (vitamin D alone or vitamin D
combined with other nutrients), study design, and characteristics of
study populations are some of the possible reasons explaining dis-
crepant results regarding the eﬀect of vitamin D on mental health, in-
ﬂammation and oxidative stress markers among these studies.
4.4. Limitations
This meta-analysis has few limitations. There were few eligible
RCTs and a modest number of participants to be included in the meta-
analysis to analyze the clinical eﬀectiveness of vitamin D on mental
health, and biomarkers of inﬂammation and oxidative stress. Due to the
heterogeneity between studies, as a result of the variations in duration
of vitamin D supplementation, the dosage or frequency of vitamin D
used, the results of this meta-analysis should be interpreted with cau-
tion.
5. Conclusions
Overall, the current meta-analysis demonstrated that vitamin D
supplementation among patients with psychiatric disorders had bene-
ﬁcial eﬀects on BDI, PSQI, GSH, TAC and CRP levels, but did not aﬀect
other biomarkers of inﬂammation and oxidative stress.
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